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Open access under CC BYInterest in snus (Swedish type moist snuff) as an alternative to smoking is increasing, but the evidence on
the health effects of switching from cigarettes to snus has not previously been reviewed. We identiﬁed six
epidemiological cohort or case-control studies, all from Sweden, which allowed comparison of cancer or
cardiovascular disease risk in current snus users who formerly smoked (‘‘switchers’’) with that of never
snus users who continued to smoke (‘‘continuers’’) or of never snus users who quit smoking (‘‘quitters’’).
Based on 13 sets of comparisons, one for oral cancer, one for stomach cancer and 11 for various cardio-
vascular disease endpoints, switchers were consistently found to have a lower risk than continuers, with
relative risks varying from 0.35 to 0.61, and a similar risk to quitters. Based on estimates from four studies
for ischaemic/coronary heart disease or acute myocardial infarction, meta-analyses gave combined rela-
tive risk estimates of 0.55 (95% conﬁdence interval 0.45–0.68) for switchers vs. continuers and 1.02 (95%
conﬁdence interval 0.83–1.26) for switchers vs. quitters. Though based on limited evidence with some
weaknesses, these results are consistent with a recent review which found no increased risk of cancer
or heart disease from snus use.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Swedish-type moist snuff (‘‘snus’’) consists of ﬁnely ground
air- or sun-cured tobacco, salt (sodium chloride), water, humidify-
ing agents, chemical buffering agents (sodium carbonate), and
food-grade ﬂavourings. The tobacco is often heat-treated (pasteur-
ized). In the past, a pinch (or dip) was placed between the gum
and upper lip, often for 11–14 h daily (International Agency for
Research on Cancer, 2007a), but more recently the commonest
application method is by portion-packed tobacco in a small sachet
(similar to a tea-bag). Use involves overall nicotine exposure similar
to and perhaps somewhat greater than that from smoking (Agewall
et al., 2002; Bolinder et al., 1997a,b; Bolinder and de Faire, 1998;
Eliasson et al., 1991; Holm et al., 1992; Wennmalm et al., 1991).
Although the sale of snus is banned in other EU countries, Sweden
has a special derogation due to its long history of use.
In the last decade, there has been increasing interest in snus as a
possible safer alternative to smoking. Various reviews (e.g. Boffetta
et al., 2008; Broadstock, 2007; Kallischnigg et al., 2008; Lee, 2007;
Lee and Hamling, 2009; Scientiﬁc Committee on Emerging and
Newly Identiﬁed Health Risks (SCENIHR), 2008; Weitkunat et al.,n; BMI, body mass index;
CVD, cardiovascular disease;
ive risk; SCD, sudden cardiac
-NC-ND license. 2007) have considered possible health effects, and oral and pancre-
atic cancer, oral disease and cardiovascular disease (CVD) have re-
ceived particular attention.
A recent summary, with meta-analyses, of the epidemiological
evidence relating snus to health (Lee, 2011) found no statistically
signiﬁcant association with cancer of any site or with heart disease
or stroke, and concluded that any possible risk from snus, if it ex-
ists, is much less than that from smoking. It also noted that ‘‘snuff
dipper’s lesion’’ (Axéll et al., 1976) does not predict oral cancer.
Though that summary considered a wide range of possible health
effects, and also found no reliable evidence that snus increases ini-
tiation of smoking or discourages quitting, it did not evaluate
health effects associated speciﬁcally with switching from smoking
to snus. Such an evaluation is reported here, by comparing switch-
ers with those who continue to smoke or who quit smoking rather
than switch.2. Materials and methods
The searches concerned all those health effects considered in
sections 3.1 (cancer), 3.2 (non-neoplastic oral disease), 3.3 (circula-
tory disease) and 3.7–3.14 (diseases of the respiratory and digestive
system; psychiatric, neurodegenerative and musculoskeletal disor-
ders; pregnancy and reproductive effects; all-cause mortality; and
general health indicators) of the 2011 summary review of snus
and health (Lee, 2011). All the publications which were cited in that
review on these health effects, as well as additional publications
2 P.N. Lee / Regulatory Toxicology and Pharmacology 66 (2013) 1–5obtained by updating the literature search to September 2012 using
the same search criteria as used in the 2011 summary, were consid-
ered. All these publications were then examined to assess whether
they presented results allowing comparison of risk in current snus
userswho had formerly smoked (‘‘switchers’’) current smokerswho
had never used snus (‘‘continuers’’) and former smokers who had
never used snus (‘‘quitters’’). We also accepted results where data
were given for similar deﬁnitions (e.g. current smokers who did
not currently use snus may also be considered continuers), though
such differences in deﬁnition are made clear when presenting the
ﬁndings.
Studies presenting relevant data generally presented their ﬁnd-
ings as a set of covariate-adjusted relative risks (RRs) or odds ratios
(ORs) with 95% conﬁdence limits (CIs) for a two-way table of smok-
ing by snus use (e.g. never/current/former smoking  never/cur-
rent/former snus), with the RRs and ORs presented relative to
those who had never smoked or used snus. As we wished to com-
pare risks between switchers and continuers, and between switch-
ers and quitters, the method of Hamling et al., 2008) was used to
derive ‘‘pseudo-numbers’’ of cases and controls (or at risk) corre-
sponding to the adjusted RRs or ORs given,which could then be used
to derive the required estimates. Where adjusted RRs were not pro-
vided, estimates were based on the given numbers of cases and
controls.
Where appropriate, meta-analyses of estimates were derived
using standard methods (Fleiss and Gross, 1991).3. Results
The literature searches identiﬁed six studies, all cited in the
2011 review. Two were of cancer (Schildt et al., 1998; Ye et al.,
1999) and four were of cardiovascular disease (CVD) (Hansson
et al., 2009; Hergens et al., 2005; Johansson et al., 2005; Wennberg
et al., 2007). All were conducted in Sweden, one based on a random
national sample (Johansson et al., 2005), one based on the Swedish
twin registry (Hansson et al., 2009), and the rest in deﬁned coun-
ties of Sweden.
Table 1 summarizes some features of the studies. Two studies
were of prospective cohort design (Hansson et al., 2009; Johansson
et al., 2005), three were case-control studies (Hergens et al., 2005;Table 1
Studies providing relevant evidence.
Reference Source
table
Study
designa
Timingb Sexc Age (years)
Schildt et al.,
1998
III CCP 1980–1989 M,F Mean 69.6 (M),
Mean 72.3 (F)
Ye et al., 1999 VII CCP 1989–1995 M,F 40–79
Hansson et al.,
2009
2 PCg 1998–2002,
4.9 years
M 40+
Hergens et al.,
2005
3 CCP 1992–1994 M 45–70
Johansson
et al., 2005
3 PCh 1988–1989,
12 years
M 30–74
Wennberg
et al., 2007
2,3 NCC 1985–1999i M Mean 53.9
a CCP = case-control study with population controls, PC = prospective cohort study, NC
b The timing of the initial interviews is given, and then the length of follow-up for pr
c M = male, F = female.
d N = never used, X = former user, C = current user, E = ever user, Non-C = non-current
e AMI = acute myocardial infarction, CHD = coronary heart disease, CVD = cardiovascu
death.
f The source table gives 15 cases and 10 controls for switchers, but these have been tak
tables.
g The study involved 16.642 subjects.
h The study involved 3120 subjects.
i Initial interviews were carried out in 1985–1999, and all cases occurring after inter
j For current smokers only, snus users were subdivided by current or non-current usSchildt et al., 1998; Ye et al., 1999), and one was a nested
case-control study, with initial interviews taking place over the
period 1980–2002 (Wennberg et al., 2007). The two cancer studies
considered both sexes, while the four studies of CVD were re-
stricted to men. All the studies provided RRs or ORs adjusted for
age and other covariates, though for one study (Schildt et al.,
1998), where the adjusted ORs had been derived by ﬁtting a mul-
tiplicative model, unadjusted ORs were used instead. Details of the
adjustment factors used are given later, in Tables 2 and 3.
In three of the studies (Hansson et al., 2009; Hergens et al.,
2005; Schildt et al., 1998), the relevant results came from tables
in which subjects were jointly classiﬁed in a 3  3 table of never/
former/current snus use by never/former/current smoking. The
classiﬁcation in a fourth study (Wennberg et al., 2007) was similar,
except that for current smokers snus use was only divided into cur-
rent/non-current. In the remaining two studies, the results were
presented as a 2  3 table with the same three-level classiﬁcation
of smoking, but only a two-level classiﬁcation of snus use, either
never/ever (Ye et al., 1999) or non-current/current (Johansson
et al., 2005).
The six studies reported results for between one and four end-
points, giving a total of 13 data sets. The results reported essentially
relate to men, as the four CVD studies were of men, Ye et al. (1999)
only presented results for snus for men, and though Schildt et al.
(1998) presented results for the sexes combined, they noted that
only onewoman reported snus use. The two cancer studies involved
between 300 and 400 cases of the cancer studied, either oral or gas-
tric. Three of the studies of CVD were larger, involving over 1000
cases, while the fourth involved 277 cases. Numbers of cases were
smaller for the subdivisions of acute myocardial infarction (AMI)
or of CVD, but still exceeded 250, except for the cases of fatal AMI
in 28 days, and of sudden cardiac death (SCD) in either <24 h or
<1 h, in the nested case-control study (Wennberg et al., 2007). Num-
bers of cases in switchers are not always available, but are substan-
tially lower. They form less than 10% of cases, and are usually
deﬁned as current snus users who formerly smoked, except in the
study of gastric cancer (Ye et al., 1999), where switchers are deﬁned
as ever snus users who formerly smoked. Some of this groupmay in
fact not have switched from smoking to snus, possibly having given
up snus before they quit smoking.Data on ST
used
Endpoints (cases, cases in switchers)e
N,X,C Oral cancer (354,10f)
N,E Gastric cancer (375,56)
N,X,C All CVD (1119,58), IHD (760,43), Stroke (416,17)
N,X,C AMI (1432,NA), Nonfatal AMI (1173,NA), Fatal AMI (259,NA)
Non-C,C CHD (277,NA)
N,X,Cj AMI (1668,138), Fatal AMI in 28 days (103,7), SCD,survival <24 h
(83,6), SCD,survival <1 h (49,5)
C = nested case-control study.
ospective cohort studies.
user.
lar disease, IHD = ischaemic heart disease, NA = not available, SCD = sudden cardiac
en as 10 cases and 15 controls, so that the total numbers align with the data in other
view in this period were considered in analysis.
e.
Table 2
Comparison of health risks in switchers (from smoking to snus) and in continuing smokers.
Reference Endpoint Continuing smokers: (current smokers
who never used snus)
Switchers: (former smokers who
currently use snus)
Switchers
RR/OR (95% CI) (vs never tobacco) RR/OR (95% CI) (vs never tobacco) RR/OR (95% CI) (vs
continuers)
Adjustment
factors
Cancer
Schildt et al., 1998 Oral cancer 1.78 (1.22–2.62) 0.77 (0.34–1.79) 0.43 (0.18–1.02) None
Ye et al., 1999 Gastric cancer 2.00 (1.30–2.90) 1.20 (0.80–1.90)a 0.60 (0.38–0.95) Age,othersb
CVD
Hansson et al., 2009 Total CVD 1.86 (1.56–2.22) 1.04 (0.78–1.39) 0.56 (0.41–0.75) Age,othersc
IHD 1.99 (1.59–2.50) 1.22 (0.82–1.74) 0.61 (0.42–0.90) Age,othersc
Stroke 1.61 (1.22–2.13) 0.77 (0.46–1.29) 0.48 (0.28–0.82) Age,othersc
Hergens et al., 2005 Total AMI 2.80 (2.30–3.40) 1.60 (1.10–2.20) 0.57 (0.40–0.81) Age,area
Non-fatal AMI 2.70 (2.20–3.30) 1.60 (1.10–2.20) 0.59 (0.42–0.83) Age,area
Fatal AMI 3.60 (2.40–5.20) 1.50 (0.69–3.20) 0.42 (0.20–0.86) Age,area
Johansson et al., 2005 CHD 2.30 (1.66–3.19)d 1.18 (0.67–2.06) 0.51 (0.30–0.88) Age,otherse
Wennberg et al., 2007 Total AMI 2.60 (1.91–3.54)d 1.25 (0.80–1.96) 0.48 (0.30–0.76) Age,othersf
Fatal AMI in
28 days
3.53 (1.83–6.84)d 1.24 (0.44–3.53) 0.35 (0.12–1.02) Age,othersf
SCD with
survival <24 h
3.12 (1.53–6.33)d 1.39 (0.44–4.42) 0.45 (0.14–1.45) Age,othersf
SCD with
survival <1 h
4.54 (1.55–13.25)d 2.67 (0.52–13.80) 0.59 (0.10–3.53) Age,othersf
Meta-analysis of IHD/CHD/AMI
(estimates in bold)
0.55 (0.45–0.68)g
Note: estimates used in meta-analysis are shown in bold face.
a Former smoking, ever snus.
b Adjusted for age, area of residence, BMI, socioeconomic status and alcohol consumption.
c Adjusted for age, diabetes, high blood pressure and cholesterol.
d Current smoking, non-current snus.
e Adjusted for age, physical activity, BMI, diabetes and hypertension.
f Adjusted for age, physical activity, BMI, education and cholesterol level.
g Chisquared for heterogeneity 0.726 on 3 d.f. (p > 0.50).
Table 3
Comparison of health risks in switchers (from smoking to snus) and in smokers who quit tobacco.
Reference Endpoint Quitters: (former smokers who
never used snus)
Switchers: (former smokers who
currently use snus)
Switchers
RR/OR (95% CI) (vs never
tobacco)
RR/OR (95% CI) (vs never tobacco) RR/OR (95% CI) (vs
continuers)
Adjustment
factors
Cancer
Schildt et al., 1998 Oral cancer 0.94 (0.61–1.44) 0.77 (0.34–1.79) 0.83 (0.34–1.99) None
Ye et al., 1999 Gastric cancer 1.20 (0.90–1.80) 1.20 (0.80–1.90)a 1.00 (0.66–1.51) Age,othersb
CVD
Hansson et al., 2009 Total CVD 1.17 (1.00–1.38) 1.04 (0.78–1.39) 0.89 (0.67–1.19) Age,othersc
IHD 1.34 (1.10–1.64) 1.22 (0.82–1.74) 0.91 (0.63–1.32) Age,othersc
Stroke 1.01 (0.78–1.30) 0.77 (0.46–1.29) 0.76 (0.45–1.28) Age,othersc
Hergens et al., 2005 Total AMI 1.30 (1.10–1.60) 1.60 (1.10–2.20) 1.23 (0.87–1.73) Age,area
Non-fatal AMI 1.20 (0.98–1.50) 1.60 (1.10–2.20) 1.33 (0.94–1.88) Age,area
Fatal AMI 1.70 (0.10–2.60) 1.50 (0.69–3.20) 0.88 (0.42–1.87) Age,area
Johansson et al., 2005 CHD 1.47 (1.07–2.03)d 1.18 (0.67–2.06) 0.80 (0.47–1.38) Age,otherse
Wennberg et al., 2007 Total AMI 1.18 (0.82–1.70) 1.25 (0.80–1.96) 1.06 (0.64–1.75) Age,othersf
Fatal AMI in
28 days
1.02 (0.45–2.31) 1.24 (0.44–3.53) 1.22 (0.38–3.90) Age,othersf
SCD with
survival <24 h
0.74 (0.28–1.97) 1.39 (0.44–4.42) 1.88 (0.48–7.27) Age,othersf
SCD with
survival <1 h
0.35 (0.07–1.78) 2.67 (0.52–13.80) 7.63 (0.42–137.8) Age,othersf
Meta-analysis of IHD/CHD/AMI
(estimates in bold)
1.02 (0.83–1.26)g
Note: estimates used in meta-analysis are shown in bold face.
a Former smoking, ever snus.
b Adjusted for age, area of residence, BMI, socioeconomic status and alcohol consumption.
c Adjusted for age, diabetes, high blood pressure and cholesterol.
d Former smoking, non-current snus.
e Adjusted for age, physical activity, BMI, diabetes and hypertension.
f Adjusted for age, physical activity, BMI, education and cholesterol level.
g Chisquared for heterogeneity 2.309 on 3 d.f. (p > 0.50).
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each expressed relative to those who had never used tobacco. In
all 13 data sets, the risk of disease in continuing smokers issigniﬁcantly (p < 0.05) elevated, with relative risk estimates
varying between 1.61 and 4.54. In switchers, however, the risk is
signiﬁcantly (p < 0.05) elevated in only two data sets. These two
4 P.N. Lee / Regulatory Toxicology and Pharmacology 66 (2013) 1–5estimates, for AMI and non-fatal AMI from the same study (Her-
gens et al., 2005), are clearly not independent, as the 1173 non-
fatal cases formed 82% of the total of 1432 cases of AMI.
Table 2 also shows that the RRs/ORs for switchers, expressed rel-
ative to continuers, are very consistent, varying only from 0.35 to
0.61. Nine of these 13 estimates show a signiﬁcantly (p < 0.05) low-
er risk in switchers, the only exceptions being where numbers of
cases in switchers are low (10 or less). In view of the variety of end-
points and the non-independence of some of the results, meta-anal-
ysis of all 13 estimates is not meaningful. However, it is reasonable
to combine the single estimates for IHD, coronary heart disease
(CHD) or total AMI from the four studies of CVD. These four esti-
mates, shown in bold face in Table 2, are statistically homogenous
(p > 0.50). Combined, they give an estimate of 0.55 (95% CI 0.45–
0.68), consistent with switching to snus being associated with an
approximate halving of the relative risk associated with smoking.
Table 3 gives RR and OR estimates for quitters and switchers,
each expressed relative to those who had never used tobacco,
and also gives estimates for switchers, expressed relative to quit-
ters. There is no signiﬁcant evidence of a difference between
switchers and quitters in any of the data sets. Again, the estimates
for IHD, CHD or total AMI are statistically homogenous (p > 0.50).
Here the combined estimate of 1.02 (95% CI 0.83–1.26) is consis-
tent with switching to snus being associated with essentially the
same risk as quitting smoking.4. Discussion
The results summarized in Tables 2 and 3 consistently show
that switching from smoking to snus is associated with a reduction
in risk of the endpoints studied, and that switching to snus appears
to involve much the same risk as quitting smoking.
A number of limitations of the analyses should be noted. Firstly,
the number of studies providing relevant data is low, particularly
for cancerwhere theonly evidenceavailable is fromonestudyoforal
cancer (Schildt et al., 1998) and one of gastric cancer (Ye et al., 1999).
Second, the evidence is essentially restricted to men. Third, none of
the studies provide any information on how risk varies by time of
switch to snus. While there are plenty of other data on the time
course of the decline in risk followingquitting smoking (e.g. Interna-
tionalAgency for ResearchonCancer, 2007b), the studies considered
in this review do not allow comparison of duration of switching
among the switchers with duration of quitting among the quitters.
Fourth, our deﬁnition of switching, though the best there is from
the available data, does not separate those who switched immedi-
ately from smoking to snus, thosewho took up snus some time after
quitting smoking, or those who ended up as snus only users after a
period of dual use. Next, the endpoints considered vary from study
to study. Only for CVD was it reasonable to carry out any sort of
meta-analysis, combining estimates for IHD, CHD and total AMI.
Also, the deﬁnitions of the groups being compared are not
completely consistent from study to study. Finally, it should be
noted that while the analyses, with one exception, are adjusted for
age and other risk factors, none of the analyses adjust for aspects
of smoking which might bias the comparison. Thus, cigarette con-
sumption in switchers at the time they switched may differ from
that in continuers, or in quitters at the time they quit, while compar-
isons may also be biased by lack of control for duration of smoking.
Despite these potential weaknesses, the consistency of the ﬁnd-
ings is remarkable. All 13 of the RR or OR estimates comparing
switchers and continuers are in the range 0.35–0.61, while all of
the estimates comparing switchers and quitters are 0.76 or over
and did not signiﬁcantly (p < 0.05) differ from 1.0.
The ﬁndings are also consistent with those of a recent detailed
review of the epidemiological evidence on snus and health(Lee, 2011). For the endpoints considered here, the meta-analyses
in that review showed no evidence of an association with oropha-
ryngeal cancer, with combined RR or OR estimates of 0.97 (95% CI
0.68–1.37) based on 7 studies, or with stomach cancer (0.98, 0.82–
1.17, n = 5), IHD/AMI (1.01, 0.91–1.12, n = 9), stroke (1.05, 0.95–
1.15, n = 6), or any circulatory disease (1.08, 0.92–1.27, n = 5).
These meta-analyses are based on results for smokers and non-
smokers combined, with adjustment for smoking; estimates based
on results for never smokers similarly show no evidence of an in-
creased risk associated with snus use. The earlier review (Lee,
2011) concluded that ‘‘Using snus is clearly much safer than smok-
ing. While smoking substantially increases the risk of cancer and
CID, any increase from snus use is undemonstrated, and if it exists
is probably about 1% of that from smoking’’.5. Conclusion
Though based on a somewhat limited database, the ﬁndings
consistently demonstrate that switching from cigarettes to snus
is associated with a clearly lower risk of CVD and cancer than is
continuing to smoke. The risk in switchers is no different from that
in smokers who quit smoking. The ﬁndings are consistent with
other evidence that adverse health effects of snus are at most
minimal.Conﬂict of Interest statement
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